Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?

Radiother Oncol. 2007 Nov;85(2):178-86. doi: 10.1016/j.radonc.2007.07.003. Epub 2007 Aug 23.

Abstract

Background and purpose: To evaluate the input of FDG-PET data in the implementation of the involved-node radiotherapy concept and dose painting.

Materials and methods: Patients with early-stage Hodgkin lymphoma treated with combined modality treatments. First, patients underwent a PET/CT before chemotherapy in the treatment position using a head and shoulder immobilization mask. Second, all patients had a CT simulation for treatment planning. The CT simulation was coregistered with the prechemotherapy CT and FDG-PET scan. All prechemotherapy volumes were superimposed on the CT simulation. The initially involved lymph node areas to be irradiated were delineated on the CT simulation scan. Chemotherapy-induced shrinkage rates of the tumor masses visible on CT scan and on FDG-PET were determined and compared.

Results: Before chemotherapy, FDG-PET-avid areas represented 25% of the total volume on CT. After chemotherapy, the influence of initial FDG-PET data on the delineation of involved-node radiotherapy fields was significant and was due to the fact that in 36% of the patients, FDG-PET helped pinpoint lymph nodes that were undetected on CT. After chemotherapy, the rates of tumor volume shrinkage on CT and FDG-PET were similar. This finding suggests similar chemosensitivity for FDG-PET-avid and non-avid areas. There was no correlation between initial FDG-PET-avid volumes and the clinical outcome.

Conclusion: Prechemotherapy FDG-PET data are essential for correctly implementing the involved-node radiotherapy concept but seem to be of minimal value for applying the concept of dose painting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Fluorodeoxyglucose F18
  • Hodgkin Disease / diagnostic imaging*
  • Hodgkin Disease / radiotherapy*
  • Humans
  • Male
  • Positron-Emission Tomography*
  • Radiotherapy Planning, Computer-Assisted / methods*
  • Tomography, X-Ray Computed
  • Tumor Burden

Substances

  • Fluorodeoxyglucose F18